Canada: Proposed New Regulations For PM(NOC) Proceedings And CSPs

On July 15, 2017 the government published proposed new Regulations to change the procedure under the Patented Medicines (Notice of Compliance) Regulations to fundamentally change the process from a paper-based court application to a full-blown patent infringement/validity trial, complete with documentary and oral discoveries and live testimony at trial. These new Regulations could come into effect as soon as September 21, 2017. This elimination of the summary proceedings is consistent with the US Orange Book regime under Hatch-Waxman.

Like an animal designed by committee, the current PM(NOC) regime is oddly eccentric and unpopular with all parties concerned. The court had only a paper record upon which to decide often complicated technical evidence. The burden of proof was on the Innovator (the first person or patent owner) to prove that the allegations of non-infringement and invalidity made by the Generic (second person) in the Notice of Allegation were not justified. Appeals by Innovators from unsuccessful applications were moot, because the Notice of Compliance (NOA) had already issued. An unsuccessful application was often followed by a patent infringement and validity lawsuit, resulting in the duplication of efforts by the parties and the court.

By agreeing to the Canada-European Union Comprehensive Economic and Trade Agreement ("CETA"), Canada committed to providing full appeal rights under the Regulations that linked the approval of generic medicines to the protection of patent rights. That commitment necessitated replacing the PM(NOC) court application with a single, fast-tracked, patent infringement/validity trial.

The proposed Regulations will put a greater burden on the parties and the court to have the patent infringement/validity trial proceed to trial and a decision within the 24 month time limit. Wisely, the proposed Regulations provide a limited number of procedural rules and otherwise leave most procedural matters to be dealt with by the Court, to evolve procedural solutions as experience develops.

24 Month Timeline retained

The proposed Regulations would continue the current practice of barring the Minister of Health for up to 24 months from issuing a Notice of Compliance. Also maintained is the requirement that the PM(NOC) action be disposed of within 24 months of commencement of the litigation. From a Canadian perspective, this would be a "fast-track" to trial.

The "first person" and/or the patent owner can sue a "second person" for patent infringement on the basis of the second person's regulatory submission or supplement.  The second person can defend the action and commence a counterclaim to invalidate the patent. No longer at issue will be the question as to whether the Minister of Health should be prohibited from issuing a NOC. The burdens of proof under the new regime would be consistent with those of traditional patent litigation.  The proposed regulations would deem a second person to be an "interested person" who could commence invalidity proceedings.

Under the proposed Regulations, any claim in a patent included on the Patent Register could be addressed and PM(NOC) proceedings would no longer be limited to claims for the medicinal ingredient, the formulation, the dosage form or the use of the medicinal ingredient.

Joinder of other causes of action would be limited. All actions alleging infringement of a patent that could not be litigated under the Regulations, cannot be joined.  Joinder would be possible of separate actions brought by a first person and a patent owner in response to the same NOA as could separate actions brought in response to multiple NOAs that address different patents but relate to the same submission. Patents that could have been litigated in respect of the patent listed on the Patent Register and addressed in an NOA will be prohibited from being litigated afterwards unless the first person or patent owner did not have a reasonable basis for bringing an action under the Regulations within the prescribed period.


Under the proposed Regulations, a second person would still have to serve a NOA on a first-person, but greater detail would have to be provided as to invalidity allegations. A second person would have to provide a detailed legal and factual basis for any allegation of invalidity along with electronic copies of any document relied on in support of the allegation. The second person may ask for and be provided with contact information for any inventor and may request laboratory notebooks, research reports or other documents relevant to establishing the existence of a particular property, advantage or use asserted by the second person to form part of the invention as of the filing date of the application for the patent. The provision of contact information of ex-employees may put an Innovator at risk of breaching European privacy laws.

With respect to non-infringement allegations, the second person must serve, along with its NOA, any portions of its submission or supplement that could be relevant for determining whether a listed patent would be infringed. This will permit a first person or patent owner to determine whether they believe a listed patent will be infringed. A first person or patent owner may move for production of further portions of the submission or supplement after commencing a proceeding.


Because some of the documents are produced before the discovery process begins, the proposed Regulations allow for a party producing such documents to impose reasonable rules for maintaining their confidentiality, as between the parties. With respect to the court's handling of such documents, it can either adopt the rules designed by the parties or create its own conditions, as it considers just.

Case Management

The Regulatory Impact Analysis Statement says that "[e]arly and active case management will help contribute to the timely resolution of proceedings." That is an understatement. Having a pharmaceutical patent case go to trial and be decided within 24 months will require aggressive case management and cooperation between the parties. Parties and their counsel will be required to act diligently in carrying out their obligations under the proposed Regulations and to cooperate reasonably in expediting any infringement action. Failure to do so may result in the shortening or extension of the 24 month period during which the Minister is prohibited from issuing a NOC and may result in cost sanctions.

The Regulations propose case management for all cases brought under them. A case management conference would be convened shortly after a proceeding is commenced to discuss scheduling, compliance with obligations to provide documents and information, confidentiality rules, whether a sample of the generic product is needed for testing, how claim charts can best be used to expedite resolution, the timing and service of expert evidence and the most efficient and effective means of educating the court about scientific or technological matters.

Interlocutory orders could be appealed but only to the Federal Court of Appeal, with leave.


The proposed Regulations would continue to allow a second person to seek compensation for losses suffered during the period they were kept off the market as a result of an unsuccessful or discontinued proceeding. All plaintiffs would be made jointly and severally liable for losses suffered by the second person starting after the later of either the date of service of the NOA or the date when the NOC would have issued in the absence of the Regulations. Liability would no longer be limited to losses suffered prior to a specified end date.

Transitional Provisions

The proposed Regulations would come into force on the day section 59 of the CETA comes into force (currently set for September 21, 2017) and would apply to any matters other than those that arose or would arise in relation to a NOA that was served before that date.

Input to Government

Interested persons have only until July 31, 2017 to make representations on the proposed Regulations.

Certificate of Supplementary Protection (CSP)

Additional regulations adopt a patent term extension of up to two years under a Certificate of Supplementary Protection (CSP) analogous to the European Supplementary Protection Certificate (SPC) system.

In summary, a CSP extends the term of an eligible pharmaceutical patent by the difference between the date of the filing of the application for the patent and the date of issuance of the authorization for sale (Notice of Compliance), reduced by five years, and capped at two years. Patents relating to human and veterinary drugs are eligible. CSPs can only be granted for medicines for which regulatory approval in Canada has been granted, and within a prescribed time of applying to do so in another jurisdiction if Canada was not the first country in which approval was sought, and there are other timing requirements. There are also provisions designed to preclude CSPs for variations of medicines for which regulatory approval has been previously granted e.g. enantiomers or formulations, and there can be only one CSP for a medicine. Pure process patent claims are not eligible.

CSPs will be administered by the Minister of Health. The Patent Act  had previously been amended to facilitate the framework for CSPs. As with the proposed Regulations, interested parties have until July 31 to provide comment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions